undamentalytics Newsletter

Aflac income statement

In fiscal 2025, Aflac reported revenue of $17.16bn, down 9.3% on the year before and net income of $3.65bn, or $6.82 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Aflac: income statement, annual
Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue18.320.722.225.423.922.720.922.621.721.822.322.121.619.118.718.917.218.1
Selling, general and administrative2.02.22.32.42.22.32.62.82.83.03.13.43.53.23.23.03.33.2
Operating income3.44.04.54.74.44.34.04.14.14.44.54.44.94.2————
Interest expense0.10.10.20.30.30.30.30.30.20.20.20.20.20.20.20.20.20.2
Provision for credit losses—————————————0.00.10.30.20.2
Income before tax2.23.63.04.34.84.53.94.14.04.04.44.25.24.95.36.44.55.8
Income tax0.71.21.01.41.71.51.31.4−0.61.11.1−0.61.00.50.61.00.90.9
Net income1.52.31.92.93.23.02.52.74.62.93.34.84.24.44.75.43.64.9
Diluted EPS$1.59$2.46$2.06$3.06$3.38$3.25$2.92$3.21$5.77$3.77$4.43$6.67$6.25$6.93$7.78$9.63$6.82$9.37
Diluted shares (average)938m946m939m939m935m908m866m828m798m775m746m716m677m638m599m565m535m519m
EBITDA3.54.14.64.74.54.34.14.24.14.44.54.55.04.2————

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AFL vs LNCAFL vs PFGAFL vs CRBG

More: Life & Health Insurance stocks compared, Financials sector, rankings of US companies

Figures from Aflac's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aflac.